Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by AYSEGUL A SAHIN and KIM-ANH DO.
AYSEGUL A SAHIN
Connection Strength
0.516
KIM-ANH DO
  1. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011; 6(8):e23543.
    View in: PubMed
    Score: 0.050
  2. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.
    View in: PubMed
    Score: 0.050
  3. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.043
  4. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002.
    View in: PubMed
    Score: 0.036
  5. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
    View in: PubMed
    Score: 0.033
  6. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
    View in: PubMed
    Score: 0.032
  7. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat. 2014 Sep; 147(2):381-7.
    View in: PubMed
    Score: 0.031
  8. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
    View in: PubMed
    Score: 0.030
  9. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.030
  10. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat. 2014 Jan; 143(1):189-201.
    View in: PubMed
    Score: 0.029
  11. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013; 18(5):493-500.
    View in: PubMed
    Score: 0.028
  12. Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):917-24.
    View in: PubMed
    Score: 0.028
  13. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis. 2013 Mar; 34(3):587-94.
    View in: PubMed
    Score: 0.027
  14. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012 Mar 15; 118(6):1498-506.
    View in: PubMed
    Score: 0.025
  15. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
    View in: PubMed
    Score: 0.025
  16. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol. 2007 Oct 01; 25(28):4438-44.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.